4//SEC Filing
Doebele Robert 4
Accession 0001999371-24-000958
CIK 0001724979other
Filed
Jan 25, 7:00 PM ET
Accepted
Jan 26, 4:36 PM ET
Size
31.5 KB
Accession
0001999371-24-000958
Insider Transaction Report
Form 4
Doebele Robert
EVP, Chief Scientific Officer
Transactions
- Disposition from Tender
Common Stock, par value $0.001 per share
2024-01-26−476,827→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−13,890→ 0 totalExercise: $3.95→ Common Stock (13,890 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−112,206→ 0 totalExercise: $9.59→ Common Stock (112,206 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−99,400→ 0 totalExercise: $1.21→ Common Stock (99,400 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−9,260→ 0 totalExercise: $3.95→ Common Stock (9,260 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−9,260→ 0 totalExercise: $3.13→ Common Stock (9,260 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−11,119→ 0 totalExercise: $9.59→ Common Stock (11,119 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−5,000→ 0 totalExercise: $3.95→ Common Stock (5,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−59,642→ 0 totalExercise: $12.01→ Common Stock (59,642 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−90,620→ 0 totalExercise: $4.00→ Common Stock (90,620 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−12,358→ 0 totalExercise: $12.01→ Common Stock (12,358 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−49,700→ 0 totalExercise: $1.21→ Common Stock (49,700 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-01-26−1,981→ 0 totalExercise: $4.00→ Common Stock (1,981 underlying)
Footnotes (2)
- [F1]This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right.
- [F2]Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.
Documents
Issuer
Rain Oncology Inc.
CIK 0001724979
Entity typeother
Related Parties
1- filerCIK 0001856681
Filing Metadata
- Form type
- 4
- Filed
- Jan 25, 7:00 PM ET
- Accepted
- Jan 26, 4:36 PM ET
- Size
- 31.5 KB